

**Project Number & Title 8C-013**

An assessment of an attenuated live streptomycin-dependent *Actinobacillus pleuropneumoniae* (APP) vaccine (serovar 15) delivered either intranasal (IN) or as a combination of intranasal and intramuscular injection (IM)

**Project Leader**

Dr Anke Woeckel and Dr Rob Smits

**Project Participants**

Rivalea (Australia) Pty Ltd.

**Aims and Objectives**

- Evaluation of the efficacy of an attenuated live APP vaccine to control APP in a commercial herd
- Preliminary assessment of two different commercial vaccination protocols (IN pre-weaning vs IN pre-weaning + IM 4 weeks post-weaning) on attenuated live APP vaccine compared to commercial killed APP vaccine (autogenous)
- Identification and demonstration of diagnostic measures for surveillance of an effective attenuated live APP vaccination program
- Confirmation that a challenge dose of APP at  $1 \times 10^{10}$  is sufficiently high enough to elucidate a clinical response in pigs seropositive to APP15

**Key Findings**

The current commercial APP15 vaccine provided superior immune protection compared to the new vaccine.

**Application to Industry**

- Vaccine technology to be further developed.
- Current commercial vaccine and best practice management for APP should be used.